Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Dennis Cooper, MD, Jackie Manago, RN, BSN, Vimal Patel, MD, Dale Schaar, MD PhD, Tracy Krimmel, AOCN, APRN-BC, Mary Kate McGrath, RN, APN, Anne Tyno, RN, MSN, APN-C, Roger Strair, MD PhD

Blood (2019) 134 (Supplement_1): 4485.

https://doi.org/10.1182/blood-2019-130598

Published: 2019

Journal Articles

Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)

Leylah M. Drusbosky, PhD, Salah-Eddin Komrokji, Najla Al Ali, M.Sc, Neeraj Kumar Singh, B.Tech, Chandan Kumar, MT, Sumanth Vasista, BE, Diwyanshu Sahu, M.Sc., Ganesh Naga, BT, Patil Dattatraya, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, David A Sallman, MD, Rami S. Komrokji, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 2954.

https://doi.org/10.1182/blood.V130.Suppl_1.2954.2954

Published: 2017

Journal Articles

Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study

Merav Barzilai, MD, Ilya Kirgner, MD, Martin Ellis, MD, Irit Avivi, MD, Najib Dally, MD, Uri Rozovski, Noa Lavi, MD

Blood (2017) 130 (Supplement 1): 2917.

https://doi.org/10.1182/blood.V130.Suppl_1.2917.2917

Published: 2017

Journal Articles

Current Graft-Versus-Host Disease (GVHD), Relapse-Free Survival - a Novel, Dynamic Composite Endpoint to Better Define Effectiveness Following Allogenic Hematopoietic Cell Transplantation

Scott R. Solomon, MD, Connie Sizemore, Pharm.D, Michelle Ridgeway, Xu Zhang, PhD, Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2016) 128 (22): 1170.

https://doi.org/10.1182/blood.V128.22.1170.1170

Published: 2016

Journal Articles

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation (HCT): A Single Center Analysis of 613 Adult HCT Recipients Using a Modified Composite Endpoint

Melhem Solh, MD, Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Stacey Brown, B.A., Asad Bashey, MD PhD

Blood (2016) 128 (22): 4574.

https://doi.org/10.1182/blood.V128.22.4574.4574

Published: 2016

Journal Articles

T-Cell Depletion Improves the Composite End Point Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Federico Simonetta, MD PhD, Stavroula Masouridi-Levrat, MD, Yan Beauverd, MD, Olga Tsopra, MD, Yordanka Tirefort, MD, Caroline Stephan, MD, Karolina Polchlopek, MD, Riccardo Favale, MD, Carole Dantin, MSc, Marc Ansari, MD, Eddy Roosnek, PhD, Yves Chalandon

Blood (2015) 126 (23): 3204.

https://doi.org/10.1182/blood.V126.23.3204.3204

Published: 2015

Journal Articles

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

Shernan G. Holtan, Todd E. DeFor, Aleksandr Lazaryan, Nelli Bejanyan, Mukta Arora, Claudio G. Brunstein, Bruce R. Blazar, Margaret L. MacMillan, Daniel J. Weisdorf

Blood (2015) 125 (8): 1333–1338.

https://doi.org/10.1182/blood-2014-10-609032

Published: 2015

Includes: Supplemental data

Journal Articles

What Predicts Success for a New Composite Endpoint: Graft–versus-Host Disease-Free and Relapse-Free Survival (GRFS) after Allogeneic Hematopoietic Cell Transplantation?

Shernan G. Holtan, MD, Todd E. DeFor, MS, Aleksandr Lazaryan, MD PhD MPH, Nelli Bejanyan, MD, Mukta Arora, MD MS, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Daniel J. Weisdorf, MD

Blood (2014) 124 (21): 429.

https://doi.org/10.1182/blood.V124.21.429.429

Published: 2014

Journal Articles

Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial

Ida Martinelli, Piero Ruggenenti, Irene Cetin, Giorgio Pardi, Annalisa Perna, Patrizia Vergani, Barbara Acaia, Fabio Facchinetti, Giovanni Battista La Sala, Maddalena Bozzo, Stefania Rampello, Luca Marozio, Olimpia Diadei, Giulia Gherardi, Sergio Carminati, Giuseppe Remuzzi, Pier Mannuccio Mannucci

Blood (2012) 119 (14): 3269–3275.

https://doi.org/10.1182/blood-2011-11-391383

Published: 2012

Includes: Supplemental data

Journal Articles

Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease

Clare Muckian, Anthony Fitzgerald, Anne O'Neill, Anna O'Byrne, Desmond J. Fitzgerald, Denis C. Shields

Blood (2002) 100 (4): 1220–1223.

https://doi.org/10.1182/blood-2002-01-0283

Published: 2002

NARROW

Incorporation of Posttransplant Cyclophosphamide (PCy) As Part of Standard Immunoprophylaxis (IP) for All Allogeneic Transplants: A Retrospective, Single Institution Study

Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)

Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study

Current Graft-Versus-Host Disease (GVHD), Relapse-Free Survival - a Novel, Dynamic Composite Endpoint to Better Define Effectiveness Following Allogenic Hematopoietic Cell Transplantation

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation (HCT): A Single Center Analysis of 613 Adult HCT Recipients Using a Modified Composite Endpoint

T-Cell Depletion Improves the Composite End Point Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

What Predicts Success for a New Composite Endpoint: Graft–versus-Host Disease-Free and Relapse-Free Survival (GRFS) after Allogeneic Hematopoietic Cell Transplantation?

Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial

Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only